![Tialis Essential IT Plc](/common/images/company/AQSE_TIA.GB.png)
- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today - - CASGEVY is one of the first medicines funded by NHS England’s...
— Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple...
– FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 – – Suzetrigine, an investigational non-opioid pain signal inhibitor, has...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 50 | 50.1 | 50 | 33 | 50 | DE |
12 | -10 | -16.6666666667 | 60 | 60 | 50 | 703 | 52.31868132 | DE |
26 | -10 | -16.6666666667 | 60 | 64.9 | 50 | 817 | 56.53637636 | DE |
52 | 5 | 11.1111111111 | 45 | 64.9 | 45 | 1078 | 55.13596231 | DE |
156 | -15 | -23.0769230769 | 65 | 74.9 | 42 | 923 | 56.4554592 | DE |
260 | -15 | -23.0769230769 | 65 | 74.9 | 42 | 923 | 56.4554592 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.